{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:56:13Z","timestamp":1788411373132,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04462-w","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T12:55:43Z","timestamp":1743252943000},"page":"2867-2875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma"],"prefix":"10.1007","volume":"57","author":[{"given":"Takuto","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"5","key":"4462_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/iju.15411","volume":"31","author":"Y Kita","year":"2024","unstructured":"Kita Y, Otsuka H, Ito K, Hara T, Shimura S, Kawahara T, Kato M, Kanamaru S, Inoue K, Ito H, Igarashi A, Sazuka T, Takamatsu D, Hashimoto K, Abe T, Naito S, Matsui Y, Nishiyama H, Kitamura H, Kobayashi T, Japan Urological Oncology Group (2024) Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan. Int J Urol 31(5):552\u2013559. https:\/\/doi.org\/10.1111\/iju.15411","journal-title":"Int J Urol"},{"issue":"12","key":"4462_CR2","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Wu C, Campbell M, Matsangou M, Petrylak DP (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125\u20131135. https:\/\/doi.org\/10.1056\/NEJMoa2035807","journal-title":"N Engl J Med"},{"issue":"10","key":"4462_CR3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, G\u00fcm\u00fc\u015f M, Mar N, Loriot Y, Fl\u00e9chon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Moreno BH, van der Heijden MS, EV-302 Trial Investigators (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"4462_CR4","unstructured":"European Association of Urology. Muscle-invasive and metastatic bladder cancer. Arnhem, The Netherlands: European Association of Urology; 2024. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer [cited 2025 Jan 29]"},{"key":"4462_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, ESMO Guidelines Committee et al (2024) ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001","journal-title":"Ann Oncol"},{"key":"4462_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Bladder Cancer. Version 6.2024 \u2013 January 17, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf. [Cited 2025 Jan 29]."},{"issue":"2","key":"4462_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, Molassiotis A, Olver I, Rapoport BL et al (2024) 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 9(2):102195. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102195","journal-title":"ESMO Open"},{"key":"4462_CR8","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Antiemesis. Version 2.2024 - September 27, 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf [Cited 2025 Jan 29]."},{"issue":"3","key":"4462_CR9","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","volume":"27","author":"ME Lacouture","year":"2022","unstructured":"Lacouture ME, Patel AB, Rosenberg JE, O\u2019Donnell PH (2022) Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 27(3):e223\u2013e232. https:\/\/doi.org\/10.1093\/oncolo\/oyac001","journal-title":"Oncologist"},{"key":"4462_CR10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. National Institutes of Health https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf [Cited 2025 Jan 29]."},{"issue":"2","key":"4462_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 11). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"4462_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely-available easy-to-use software \u201cEZR\u201d (Easy R) for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"4462_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"EY Yu","year":"2021","unstructured":"Yu EY, Petrylak DP, O\u2019Donnell PH, Lee JL, van der Heijden MS, Loriot Y et al (2021) Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV 201): a multicentre, single-arm, phase 2 trial. Lancet Oncol 22(6):872\u2013882. https:\/\/doi.org\/10.1016\/S1470-2045(21)00094-2","journal-title":"Lancet Oncol"},{"key":"4462_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.19.3409","author":"JP Nidis","year":"2000","unstructured":"Nidis JP, Hesketh PJ, Lau J (2000) Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2000.18.19.3409","journal-title":"J Clin Oncol"},{"issue":"3","key":"4462_CR15","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/cam4.5165","volume":"12","author":"N Matsubara","year":"2023","unstructured":"Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T et al (2023) Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med 12(3):2761\u20132771","journal-title":"Cancer Med"},{"key":"4462_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70368","author":"S Li","year":"2024","unstructured":"Li S, Shi Y, Dong H, Guo H, Xie Y, Sun Z et al (2024) Phase 2 trial of enfortumab vedotin in patients with previously treated locally advanced or metastatic urothelial carcinoma in China. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.70368","journal-title":"Cancer Med"},{"issue":"16","key":"4462_CR17","first-page":"4503","volume":"42","author":"YL Chia","year":"2024","unstructured":"Chia YL, Yu EY, Powles T, Flaig TW, Loriot Y, O\u2019Donnell PH et al (2024) Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer. J Clin Oncol 42(16):4503\u20134503","journal-title":"J Clin Oncol"},{"issue":"3","key":"4462_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/oncolo\/oyac001","volume":"27","author":"ME Lacouture","year":"2022","unstructured":"Lacouture ME, Patel AB, Rosenberg JE, O\u2019Donnell PH (2022) Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin. Oncologist 27(3):223\u2013232. https:\/\/doi.org\/10.1093\/oncolo\/oyac001","journal-title":"Oncologist"},{"key":"4462_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fnins.2015.00131","volume":"9","author":"EG Vichaya","year":"2015","unstructured":"Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, Heijnen CJ, Walker AK (2015) Mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci 9:131. https:\/\/doi.org\/10.3389\/fnins.2015.00131","journal-title":"Front Neurosci"},{"key":"4462_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.euros.2024.09.011","volume":"70","author":"Y Kita","year":"2024","unstructured":"Kita Y, Nomura T, Nakajima S, Yonekura S, Murakami K, Sumiyoshi T, Masui K, Goto T, Saito R, Kabashima K, Kobayashi T (2024) Safety and efficacy of prophylactic topical steroid administration for enfortumab vedotin\u2013related cutaneous toxicity. Eur Urol Open Sci 70:18\u201320. https:\/\/doi.org\/10.1016\/j.euros.2024.09.011","journal-title":"Eur Urol Open Sci"},{"issue":"14","key":"4462_CR21","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-22-3181","volume":"29","author":"RS Goodman","year":"2023","unstructured":"Goodman RS, Johnson DB, Balko JM (2023) Corticosteroids and cancer immunotherapy. Clin Cancer Res 29(14):2580\u20132587. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3181","journal-title":"Clin Cancer Res"},{"issue":"22","key":"4462_CR22","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.19.00189","volume":"37","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM (2019) Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol 37(22):1927\u20131934. https:\/\/doi.org\/10.1200\/JCO.19.00189","journal-title":"J Clin Oncol"},{"key":"4462_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70254","author":"Y Byron","year":"2024","unstructured":"Byron Y, Yegorova-Lee S, Tio M (2024) Do corticosteroids affect immunotherapy efficacy in malignancy? - A systematic review. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.70254","journal-title":"Cancer Med"},{"key":"4462_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001008784.37684.bd.20","author":"H Yamamoto","year":"2024","unstructured":"Yamamoto H, Yoneyama F, Ishii N, Soma O, Fujita N, Okamoto T et al (2024) Association between cutaneous reactions related to enfortumab vedotin and serum albumin levels in patients with advanced urothelial cancer. J Urol. https:\/\/doi.org\/10.1097\/01.JU.0001008784.37684.bd.20","journal-title":"J Urol"},{"key":"4462_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.apcsb.2020.08.003","volume":"123","author":"S Tayyab","year":"2021","unstructured":"Tayyab S, Feroz SR (2021) Serum albumin: clinical significance of drug binding and development as drug delivery vehicle. Adv Protein Chem Struct Biol 123:193\u2013218. https:\/\/doi.org\/10.1016\/bs.apcsb.2020.08.003","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"1","key":"4462_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.21873\/invivo.13843","volume":"39","author":"N Furubayashi","year":"2025","unstructured":"Furubayashi N, Negishi T, Mochida M, Kijima A, Katsuki H, Nakamura M (2025) Impact of relative dose intensity of enfortumab vedotin for advanced urothelial carcinoma. In Vivo 39(1):411\u2013418. https:\/\/doi.org\/10.21873\/invivo.13843","journal-title":"In Vivo"},{"issue":"11","key":"4462_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.14989\/ActaUrolJap_70_11_361","volume":"70","author":"H Honda","year":"2024","unstructured":"Honda H, Matsuo T, Mori S, Araki K, Mitsunari K, Ohba K et al (2024) Risk factor of cutaneous symptoms associated with enfortumab vedotin for urothelial carcinoma [in Japanese]. Hinyokika Kiyo 70(11):361\u2013366. https:\/\/doi.org\/10.14989\/ActaUrolJap_70_11_361","journal-title":"Hinyokika Kiyo"},{"key":"4462_CR28","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17115","author":"N Furubayashi","year":"2024","unstructured":"Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K et al (2024) Cutaneous and renal toxicities of enfortumab vedotin for advanced urothelial carcinoma: The UROKYU study. Anticancer Res. https:\/\/doi.org\/10.21873\/anticanres.17115","journal-title":"Anticancer Res"},{"issue":"3","key":"4462_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102090","volume":"22","author":"E Vlachou","year":"2024","unstructured":"Vlachou E, Mamtani R, Hahn NM, Johnson B 3rd, Hoffman-Censits J, Nimgaonkar V (2024) Racial differences in cutaneous events among patients receiving enfortumab vedotin. Clin Genitourin Cancer 22(3):102090. https:\/\/doi.org\/10.1016\/j.clgc.2024.102090","journal-title":"Clin Genitourin Cancer"},{"issue":"49","key":"4462_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","volume":"6","author":"E Vlachou","year":"2023","unstructured":"Vlachou E, Matoso A, McConkey D, Jing Y, Johnson BA, Hahn NM, Hoffman-Censits J (2023) Enfortumab Vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: A single-center experience and review of the literature. Eur Urol Open Sci 6(49):100\u2013103. https:\/\/doi.org\/10.1016\/j.euros.2023.01.002","journal-title":"Eur Urol Open Sci"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04462-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04462-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04462-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:44:09Z","timestamp":1757148249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04462-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4462"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04462-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideaki Miyake received honoraria from Astellas, AstraZeneca, Bayer, Eisai, Janssen, Merck, MSD, Nippon-Shinyaku, Novartis, Ono, Pfizer, Sanofi, and Takeda. Hideaki Miyake received research funding from MSD, Pfizer, and Ono.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Kobe University (IRB No. B210314).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient consent was obtained via an opt-out on the website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}